Avoid common mistakes on your manuscript.
Correction to: Adv Ther https://doi.org/10.1007/s12325-021-01722-w
The article ‘‘Natalizumab in Early Relapsing–Remitting Multiple Sclerosis: A 4-Year, Open-Label Study’’, written by Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura Balcer, Steven Galetta, Denise I. Campagnolo, Robin Avila, Lily Lee, Danette Rutledge and Robert J. Fox was originally published electronically on the publisher’s internet portal (currently SpringerLink) on May 20, 2021 without open access. The copyright of the article changed to The Author(s) 2021 and this article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/bync/4.0/. The original article has been updated.
The original article has been updated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Perumal, J., Balabanov, R., Su, R. et al. Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther 38, 3743–3744 (2021). https://doi.org/10.1007/s12325-021-01815-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-021-01815-6